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PSMA PET/MRI validation of MR textural analysis for detection of transition zone 
prostate cancer 
 
 
ABSTRACT 
 
AIM: To validate MR textural analysis (MRTA) for detection of transition zone (TZ) prostate cancer through 
comparison to co-registered prostate specific membrane antigen (PSMA) PET-MR. 
METHODS: Retrospective analysis was performed for 30 men who underwent simultaneous PSMA PET-MR 
imaging for staging of prostate cancer. Thirty texture features were derived from each manually contoured 
T2-weighted, transaxial, prostatic TZ using texture analysis software which applies a spatial band-pass filter 
and quantifies texture through histogram analysis. Texture features of the TZ were compared to PSMA 
expression on the corresponding PET images. The Benjamini-Hochberg correction controlled the false 
discovery rate at <5%. 
RESULTS: 88 T2-weighted images in 18 patients demonstrated abnormal PSMA expression within the TZ 
on PET-MR. 123 images were PSMA negative. Based on the corrected p-value of 0.005, significant 
differences between the PSMA positive and negative slices were found for 16 texture parameters: Standard 
Deviation and Mean of Positive Pixels for all spatial filters (p=<0.0001 for both at all spatial scaling factor 
{SSF} values) and Mean Intensity following filtration for SSF 3-6mm (p=0.0002 - 0.0018).  
CONCLUSION: Abnormal expression of PSMA within the TZ is associated with altered texture on T2-
weighted MR, providing validation of MRTA for the detection of TZ prostate cancer.  
 
 
Key Points: 
 Prostate transition zone (TZ) MR texture analysis may assist in prostate cancer detection. 
 Abnormal transition zone PSMA expression correlates with altered texture on T2-weighted MR. 
 TZ with abnormal PSMA expression demonstrates significantly reduced MI, SD and MPP. 
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Abbreviations: 
PZ  Peripheral zone of the prostate 
TZ  Transition zone of the prostate 
DRE  Digital rectal exam 
TRUS  Transrectal ultrasound 
MRTA MRI textural analysis 
PSMA Prostate specific membrane antigen 
mp-MRI Multiparametric MRI  
SSF  Spatial scaling factor 
MI  Mean intensity 
SD  standard deviation 
MPP  Mean of positive pixels 
AUC  Area under the receiver-operating characteristic curve 
HASTE Half-Fourier acquisition single-shot turbo spin echo imaging 
GS  Gleason Score 
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Introduction: 
Prostate cancer is the most common non-cutaneous malignancy in the western world and accounts for the 
second highest number of deaths from cancer among males [1]. The peripheral zone (PZ) of the prostate is 
the most common location where prostate cancer occurs, accounting for up to 75-85% of cases. However, 
the transition zone (TZ) has also been identified as retrospectively containing cancer in up to 25% of radical 
prostatectomy specimens [2]. Current methods of prostate cancer screening include digital rectal 
examination (DRE) and serum prostate-specific antigen level, where diagnosis relies on histological tissue 
analysis through transrectal ultrasound (TRUS) guided biopsy, transperineal biopsy or prostatectomy. More 
recently, multi-parametric magnetic resonance imaging (mp-MRI) has been a useful tool for further 
investigation of patients with suspected prostate cancer as well as for biopsy planning. Although MRI is 
increasingly recognised as a useful adjunct to DRE and TRUS in the detection of prostate cancer, even in 
combination these techniques may miss TZ tumours. In the case of DRE and TRUS, the reduced sensitivity 
for TZ tumours is due to their anterior location.  For MRI, the signal characteristics of cancer frequently 
overlap with other conditions occurring in the TZ, most commonly benign prostatic hypertrophy [3]. There is 
therefore a need for additional methods to aid the detection of prostatic cancer in the TZ.  
 
Tumours located within the transition zone often appear as a homogenous signal mass with indistinct 
margins (“erased charcoal sign”) and low signal intensity on the T2-weighted images that form the mainstay 
of the evaluation of the TZ with MRI [4]. These features can be difficult to appreciate visually but are 
potentially demonstrable using imaging processing techniques that assess the spatial heterogeneity of 
signal within tissues, known as texture analysis. Previous research has shown the potential for MR texture 
analysis (MRTA) to improve the detection of prostate cancer in general and in the TZ in particular [5, 6]. 
However, these studies used histopathological examination of tissue obtained at either radical 
prostatectomy or trans-perineal template biopsy as the reference standard and are therefore susceptible to 
errors from mis-registration between histopathology and imaging findings. MRTA therefore requires further 
validation before translation into routine clinical practice.  
 
Prostate Specific Membrane Antigen (PSMA) is a transmembrane protein which is found to be 
overexpressed on most prostate cancer cells. Through the use of a 68-Gallium radiolabelled PSMA ligand, 
PSMA-expressing prostate cancer can now be detected with PET-CT and PET-MR with sensitivity that is 
favourable compared to choline-based PET imaging techniques and CT or mp-MRI alone [7]. The accurate 
co-registration of PET and MRI afforded by PSMA PET-MR in particular, improves the localization of 
prostatic cancer in comparison to multi-parametric MRI alone [8]. PSMA PET-MR is an expensive technique 
with currently severely restricted access. However, the use of PSMA PET-MR as a reference standard in 
assessing the ability of texture analysis to detect TZ prostate cancer may help overcome the uncertainties 
associated with correlation between histological and imaging data. In this study, we hypothesise that PSMA 
PET-MR can demonstrate an association between abnormal PSMA expression within the prostatic transition 
zone and altered texture on T2-weighted MRI, thereby providing further validation for the application of 
MRTA in the detection of transition zone prostate cancer. 
 
 
Materials and Methods: 
This retrospective observational study formed part of a larger research programme for imaging biomarker 
discovery using patient data acquired as part of routine clinical care. Our local institutional review board had 
approved this programme and waived the requirement for individual consent.  
 
Patient Cohort:  
The cohort comprised consecutive male patients who had undergone simultaneous PSMA PET-MR 
including 3T multiparametric MR images of the prostate between the period of March 2015 and February 
2016 for purposes of staging prostate cancer. Patients were excluded from this study if they had previously 
received local radiotherapy, androgen therapy, brachytherapy or prostate surgery due to the alteration in 
prostate tissue appearance and impact on prostatic textural analysis. In total, 30 men with a mean age 
(range) of 65 years (50 – 81 years) were accrued. 
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Image acquisition: 
All patients underwent simultaneous PET-MR with a 3T magnet (Siemens, Biograph mMR PET-MR, 
Bayswater, Australia) following intravenous administration of 150MBq of 68Gallium-labelled PSMA ligand 
and 5mg Buscopan (to minimise bowel peristalsis). Fast view and HASTE localiser (half-Fourier acquisition 
single-shot turbo spin echo imaging) were performed initially to allow planning of the PET and subsequent 
MR sequences. 45 minutes after administration of 68Gallium-labelled PSMA ligand, MRI attenuation 
correction and T2 sagittal/coronal/axial images were then obtained simultaneously during PET acquisition 
over a 15 minute period. Once PET acquisition was complete, a further 5mg Buscopan as well as 7.5ml of 
Gadolinium via an autoinjector were administered intravenously prior to DWI and Dynamic T1 VIBE 
sequences. Complete mp-MRI parameters are provided in Table 1. To enable quantitative comparison 
between images, T2 acquisitions utilised a standardised protocol that controlled the image gain at a 
predetermine level for all patients. Collected images with evidence of TZ tumour identified on T2-MR, PSMA 
PET and fused PSMA PET-MR are seen in Figure 1.  
 
Image Analysis: 
For all patients, the entire transition zone was manually contoured on each slice of the transaxial T2-
weighted image data sets containing prostatic tissue. Using TexRAD software (Feedback PLC, Cambridge, 
UK), 30 texture features were then derived for each whole contoured TZ by applying an increasingly course 
spatial band-pass filter from 2-6mm (spatial scaling factor: SSF 2-6) with subsequent quantification of the 
texture maps through histogram analysis. Histogram features returned for each SSF value comprised 
kurtosis, skewness, mean of positive pixels (MPP), entropy, mean intensity (MI) and standard deviation 
(SD). No image thresholding was applied prior to texture analysis.  
 
PSMA PET images were then linked to the co-registered T2-weighted MR images and analysed by a single 
radiologist with specialisation in nuclear medical imaging, over 20 years of experience in PET imaging 
analysis and over 2 years of PSMA PET-MR analysis. Each individual PSMA PET image was then 
assessed for PSMA ligand uptake with positive PSMA expression defined as any region of the prostatic TZ 
containing focal radiotracer uptake greater than background uptake. Based on the corresponding PSMA 
PET image, each transaxial T2-weighted image was then classified as positive or negative for abnormal 
PSMA expression. Manually contoured T2-MR and corresponding texture maps are seen in Figure 2.  
 
Statistical Analysis: 
The Mann-Whitney test was used to compare each texture feature between slices in which abnormal PSMA 
expression was shown to be present or absent in the transition zone on the corresponding PET image. The 
Benjamini-Hochberg correction was then used to determine the p-value that would control the false 
discovery rate at <5%. The diagnostic performance for all texture parameters found to be significant after 
Benjamini-Hochberg correction was expressed as the area under the receiver-operating characteristic curve 
(AUC). All statistical analysis was performed using the online statistical computation site, vassarstats.net, 
accessed 2017.   
 
 
Results: 
Histopathological examination of prostatic tissue had been performed in 29 of the 30 patients; 19 by 
transrectal or transperineal biopsy and 20 following prostatectomy (with or without prior biopsy). The results 
are summarised in Table 2. Prostatic carcinoma was confirmed in 25 patients, all of whom demonstrated 
focally increased PSMA expression within the prostate (either the transition zone, peripheral zone or both.) 
The Gleason Scores (GS) of these tumours were: GS6: 2, GS7: 17, GS8: 1, GS 9:4, GS10: 1. No tumour 
was identified on histology in 4 cases, one of whom demonstrated focally increased radiotracer uptake in the 
TZ on PSMA-PET. 
 
18 out of 30 patients were identified to have abnormal PSMA expression within the transition zone on PSMA 
PET-MR. Of those 18 patients, 88 individual T2-weighted images were found to have positive PSMA 
expression on corresponding PET images while a total of 123 images were PSMA negative. The Mann-
Whitney test demonstrated differences between PSMA positive and negative data sets with a p-value of 
<0.05 for all SSF values for the following texture features; MI, SD, and MPP, and for kurtosis at SSF 2mm, 
skewness at SSF 4-6mm and entropy at SSF 2mm (Table 3). The corrected p-value controlling the false 
discovery rate to less than 5% was 0.005 which resulted in significant differences between PSMA positive 
4 
 
and negative images only for MPP and SD at all spatial filters, as well as MI for SSF 3-6mm. The most 
significant difference between PSMA positive and negative images was observed for MPP at SSF = 4mm 
(Figure 3), with an AUC of 0.756 on receiver-operating characteristic analysis.  
 
 
Discussion: 
Our results indicate that abnormal expression of PSMA within the prostatic transition zone is associated with 
altered texture on T2-weighted MR. With the false discovery rate controlled at 5%, significant differences 
between the texture analysis of T2-weighted MR images corresponding to positive and negative PSMA 
uptake in the TZ are seen for a range of textural features.  The parameters that were statistically different 
(after Benjamini-Hochberg correction) were MI, SD and MPP, each parameter being reduced in the 
presence of PSMA expression. As these texture values are increased when image features are highlighted 
by the image filtration step [9], our finding of reduced values in the presence of PSMA expression is 
concordant with the homogenously reduced T2 signal of TZ tumours on MRI (known as the “erased 
charcoal” appearance) [2]. As PSMA is highly expressed in prostate cancer, this association suggests that 
MRTA may potentially assist in the identification of transition zone tumours which can otherwise be difficult 
to detect on multiparametric MR alone.  
 
The use of abnormal PSMA expression on PET-MR as the reference standard distinguishes our study from 
previous reports that have assessed the potential for MRTA to aid detection of prostate cancer [5, 6]. The 
simultaneous acquisition of PET and MR images ensures highly accurate co-registration of MRI features 
with depiction of PSMA expression on PET, thereby avoiding the potential for mis-registration that can occur 
when correlating imaging with histological findings. Previous studies have sought to identify tumours with 
Gleason grade of 7 or above as these tumours are considered clinically significant. However, PSMA 
expression is found in tumours with Gleason grade of less than 7 as well in higher grade tumours, and it is 
possible that some lower grade tumours have been detected by MRTA in our study. Nevertheless, the 
diagnostic performance of MRTA for detection of TZ cancer in our study is comparable to a previous MRTA 
study by Sidhu et al and to reported visual analysis by radiologists [2, 6, 10].   
 
Although we performed MR at 3T, our results are concordant with those of Sidhu et al who reported textural 
analysis of T2 MRI performed at 1.5T in the detection of TZ prostate cancer [6] in that we also failed to find 
significant differences in kurtosis, entropy and skewness between TZ with and without tumour. Sidhu et al 
did not report results for MI, MPP and SD as they had not used a standardised MR acquisition protocol. Our 
adoption of a standardised MR acquisition protocol on a single imaging platform has allowed the inclusion of 
these texture parameters in our study, showing these parameters to be better discriminators for the 
presence of TZ cancer on T2-weighted images. 
 
Our results are subject to some study limitations beyond the retrospective, observational design. Although 
histopathological examination of prostatic tissue had been performed in all but one of our patients, the 
results of tissue sampling gave limited information as to the precise location of tumour within the prostate 
gland and no indication as to location within any specific prostatic zone (TZ or PZ).  Notwithstanding the fact 
all patients in our study with a tissue diagnosis of prostate cancer had positive PSMA expression within 
either the TZ or PZ, it remains possible that individual MR slices on T2 imaging without corresponding 
PSMA expression on PET could have contained non-PSMA expressing tumour. However, the probability of 
such occurrences is low given the reported incidence of false-negative PSMA-PET for prostate cancer of 
approximately 8% [11]. It is also possible that images with apparent PSMA expression may not have 
contained tumour either because of PSMA expression within non-malignant tissue as appeared to have 
occurred in subject 1, or due to partial volume effects resulting in an apparent lesion size on PET in excess 
of the true tumour volume.  Nonetheless, a false-detection rate is often acceptable in the diagnosis of 
cancer, particularly when associated with a concomitant reduction in false negative findings.  
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Although important, the above limitations may be off-set by the avoidance of comparable issues associated 
with the co-registration of histological features after prostatectomy with prior MRI findings, as used in 
previous studies. As similar results have been produced by both approaches, they can be considered to 
provide mutual support for the validation of MRTA as a method for the detection of TZ prostatic cancer. 
 
Our findings provide further validation for the use of MRTA as an aid to diagnosis of prostate cancer within 
the transition zone, with the potential for development of technology for Computer Aided Diagnosis. Altered 
MR texture may potentially be considered to denote an “at-risk” transition zone which could indicate biopsy 
rather than a watch-and-wait strategy when visual assessment of MRI is indeterminate (e.g. PIRADS 3 
lesion). Alternatively, abnormal MR texture could trigger further investigation with PSMA PET-CT or PET-
MR.  
 
In conclusion, this study has used PSMA PET-MR imaging to demonstrate an association between 
abnormal expression of PSMA within the prostatic transition zone and altered texture on T2-weighted MR. 
As PSMA is highly expressed in prostate cancer, this association provides validation of the the use of MRTA 
for the detection of transition zone prostate cancer.  
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Methodology:  
 retrospective 
 observational study 
 performed at one institution 
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Table and Figure Legend: 
 
Table 1. 
Parameters of multi-parametric MRI sequence used during this study.  
7.5ml of intravenous gadolinium contrast used for contrast-enhanced MRI; DWI – diffusion weighted 
imaging; VIBE - volumetric interpolated breath-hold examination.  
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Figure 1. 
Left: Attenuation corrected PSMA PET image showing high PSMA uptake within the right sided transition 
zone of the prostate and physiological uptake within the urinary bladder. Middle: Corresponding transaxial 
T2-weighted MR image showing changes characteristic of malignancy including homogenous, 
hypoattenuation of the right sided prostatic transition zone (“erased charcoal sign”). Right: Fused (co-
registered) transaxial PSMA PET-MR image showing high PSMA uptake within the right sided transitional 
zone of the prostate and physiological uptake within the urinary bladder. 
 
Figure 2. 
Unfiltered T2-weighted MR image of prostate (top left) with increasingly course spatial band-pass filtered 
images (2mm – top right, 4mm – bottom left and 6mm – bottom right). Filtered images correspond to those 
from Figure 1 with highly positive PSMA uptake seen within the right sided transition zone. 
 
Figure 3. 
Box and whisker plot of all MPP values with PSMA negative results depicted on the left and PSMA positive 
results on the right. Box plots consist of median value, upper and lower quartiles, and range.  
 
Table 2. 
Demonstrates the histopathological data, if available, for each patient involved in the study. Includes the 
presence or absence of PSMA expression within the TZ and PZ, the tissue sample analysed 
(TRUS/Transperineal biopsy and/or prostatectomy), histological subtype of prostate cancer, number of 
positive cores on biopsy for each Gleason score, and anatomical location of prostate cancer as described 
on prostatectomy histopathology report. Subject number 10 represents the sole patient who has not 
received either a biopsy or prostatectomy to date and has been followed up with repeat PSA testing at 
regular intervals. 
 
Table 3. 
Median values and ranges for PSMA positive and PSMA negative, T2-weighted image slices are shown, 
along with their corresponding P-values for all textural features and spatial band-pass filters. Statistically 
significant P-values after application of the Mann-Whitney test and Benjamini-Hochberg procedure are 
shown in red. (AUC = area under receiver-operating characteristic curve.) 
 
